Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is launching its own psychedelic facilitator training program. Called EMBARK, the project is led by expert faculty and provides psychedelic clinical trial facilitators with fundamental training to provide skillful, ethical care to individuals receiving psychedelic treatment. EMBARK emphasizes experiential learning and includes an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state as well the training and practice sessions on the EMBARK model, a groundbreaking psychotherapy approach that incorporates psychedelic medicine with leading clinical approaches designed to promote supportive healing. EMBARK’s six clinical domains include existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum. The model is adaptable to a variety of clinical indications and challenges including depression, alcohol use disorder and anxiety. “We’re excited to host this training,” said Cybin chief clinical officer and EMBARK co-author Dr. Alex Belser in the press release. “When we first created EMBARK, we canvassed 20 different psychedelic-assisted psychotherapies. We found that some therapies left out important aspects, like people’s spiritual experiences, somatic experiences or human relationships. Patients were telling us that these experiences were central to their healing, but many therapies seemed to be missing critical pieces. To address this challenge, we developed EMBARK, which provides an open architecture to support the varieties of psychedelic experience within a coherent therapeutic framework. This is a patient-centered approach for the whole person.”

To view the full press release, visit

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Cybin Inc. CYBN, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.